The presentation addresses the main challenges and the best approaches of in-depth comparative analysis of market access for breast cancer therapies, focusing on the Netherlands and benchmarking against several other countries. The research highlights critical differences in access timelines, and availability of innovative treatments. By mapping the breast cancer landscape in the Netherlands—including product availability and clinical research activity—the study identifies gaps and opportunities for accelerating patient access. In this session, you will learn:

• What differences exists on market access timelines for breast cancer therapies in the NLs vs surrounding countries
• What challenges lead to delay in market access entry and how these could be decreased/overcome
• How to analyze the impact of regulatory and reimbursement frameworks on therapy availability

• How to effectively align clinical, economic, and real-world evidence to meet diverse HTA and payer expectations?
• What are the key pitfalls in health economic modeling and budget impact analyses that jeopardize reimbursement outcomes?
• How can early engagement with the profession support the HTA process?
• How can you ensure the added value is being understood and acknowledged by the HTA-bodies/Payer?
• How can early engagement with payers and HTA bodies shape a more favorable reimbursement strategy?

Presenting the results of our World Cafés: The moderators summarize the key take-aways of their World Café Round Tables on the main stage and share the main findings with all attendees.